Study (GWAS) was carried out to look for potential SNPs associated with risk of RP grade 2. Result: The incidence of RP of grade 2 was 29.2%. Using SNP information by Genomes-Wide Association Study (GWAS), we discovered 73 SNPs that showed significant difference with cutting off p-value of 0.001. Most of them are previously not reported. Conclusion: This result established a set of biomarkers which can be used for prognosis predictions for radiation-induced pneumonitis.
P1.17-04 Curative Intent Treatment for Stage III NSCLC in England S. Harden, 1 A. Khakwani, 2 P. Beckett, 1 J.B. Adizie 1 1 Clinical Effectiveness and Evaluation Unit, Royal College of Physicians of London, London/GB, 2 Department of Epidemiology and Public Health, University of Nottingham, Ng Pb/GB Background: The National Lung Cancer Audit (NLCA) produces annual reports detailing standards of care for lung cancer. This further analysis investigates the use of curative intent multi-modality treatment for people in England diagnosed with stage III NSCLC during 2016, including, for the first time, details about use of concurrent and sequential chemoradiation (cRT). Method: Data on patients diagnosed during 2016 with stage III NSCLC in England were extracted from the National Cancer Registration and Analysis Service (NCRAS); information submitted through the Cancer Outcome and Services Dataset (COSD) were linked to other NCRAS datasets, including Hospital Episode Statistics (HES), the National Radiotherapy Dataset (RTDS) and the Systemic Anti-Cancer Dataset (SACT). Result: 6,288 cases of stage III NSCLC were analysed, 3839 Stage IIIA and 2449 Stage IIIB (Table 1) . 813 (13%) people underwent surgery with 447 (7%) of these also receiving chemotherapy (predominantly adjuvant). 1047 (17%) people were treated with radical radiotherapy with 676 (11%) of these also receiving chemotherapy. For the 589/676 cRT cases where complete treatment dates were available, 199 (34%) received concurrent and 390 (66%) received sequential chemoRT (37% and 63% for stage IIIA). For 481/589 cases with performance status (PS) available, 171 (36%) PS0-1 cases received concurrent and 310 (64%) received sequential cRT (38% and 62% for stage IIIA) Of note, 2148 (34%) people received anti-cancer treatment of palliative intent and 2290 (36%) received supportive care only. Survival data will also be presented. Table 1 Conclusion: Multi-modality treatment with either surgery or radical radiotherapy combined with chemotherapy was delivered to 1123 (18%) patients with stage III NSCLC. Concurrent cRT, optimal cRT based on meta-analysis, was delivered to just over one third of people receiving cRT, including for patients of good PS0-1. This analysis provides a baseline for future quality improvement initiatives to optimise treatment and outcomes for patients with stage III NSCLC. Background: Numerous dose fractionation regimes have been used for inoperable NSCLC patients and there is evidence that accelerated schedules can produce better outcome than conventionally fractionated treatment (1). Continuous hyperfractionated accelerated radiotherapy (CHART, 54Gy in 36 fractions over 12 days) and accelerated hypofractionated radiotherapy (55Gy in 20 fractions over 4 weeks) have been routinely used in Sheffield over the past decade, with schedule selection largely down to patient choice (inpatient vs out-patient treatment). In this single-centre retrospective analysis, we present the outcomes for all patients treated with these two schedules between 2003 to 2015. Ref 1. LePechoux C, Mauguen A, Baumann M, et al. Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis. JCO 2012;30:2788-2797. Method: In this audit details on patient demographics, tumour characteristics and survival data was collected from the electronic hospital records and supplemented by information from patient notes. Dosimetric data for tumour and organs at risk were collated automatically via the Varian Eclipse Scripting application programming interface. Descriptive statistical analysis was performed using the SSPS package with clinical and dosimetric variables assessed using independent samples t-tests and survival via a logrank test. Multivariate survival analysis was performed using Cox regression. Result: We identified 883 eligible patients, of which 45% received CHART and 55% hypofractionated radiotherapy. Mean age was 70 years and 58% were male. PET staging was performed in 87% with 30%, 15%, 51% and 4% being stage I, II, III and IV, respectively. 63% had a WHO performance status of 0-1. 38% of patients underwent induction chemotherapy. 99% completed their prescribed radiotherapy treatment with an overall response rate of 60%. Relapse was observed in 50% of patients with median disease-free survival of 19.4 months. 2-year overall survival was 47% with a median overall survival of 23.2 months. Multivariate analysis identified histology, stage, performance status, use of chemotherapy as independent predictors of survival. No significant differences between the two radiotherapy regimes was seen for any parameters. Conclusion: This audit has confirmed that both CHART and hypofractionated accelerated radiotherapy are deliverable and well tolerated schedules when used in day to day practice. We have detected no significant difference in outcome between the two schedules and there is the need to explore avenues, eg dose escalation, that develop these schedules to match outcomes reported by recent concurrent chemo-radiation studies. Background: Local recurrence after definitive chemotherapy and/or radiotherapy with curative intent is frequently experienced in patients with locally advanced lung cancer. We evaluated the frequency, feasibility, and efficacy of salvage pulmonary resection after definitive chemotherapy and/or radiotherapy. Method: We analyzed the characteristics and medical courses of consecutive patients who had undergone salvage pulmonary resection after local relapse or progression after chemotherapy, chemoradiotherapy and radiotherapy including stereotactic body radiation therapy (SBRT) and proton beam therapy (PBT). In this analysis, local relapse or progression were defined as increase in remaining tumor size or
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